Abstract
Antiepileptic hypersensitivity syndrome is a serious idiosyncratic, non-dose-related adverse reaction reported to occur with phenytoin, phenobarbital, carbamazepine, primidone, and lamotrigine. The reaction usually develops 1 to 12 weeks after initiation of therapy with one of the above agents and is recognized by the classic triad of fever, rash, and internal organ involvement. Immediate discontinuation of the suspected anticonvulsant is essential for good outcome. Patients usually are managed supportively with hydration, antihistamines, H2-receptor blockers, and topical corticosteroids. In severe cases, the use of systemic corticosteroids may be necessary. The use of intravenous immune globulin should be limited to severe cases where Kawasaki disease or idiopathic thrombocytopenic purpura cannot be ruled out. Education of health care professionals and patients is imperative to improving outcomes and prevention of this reaction in the future.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Tafreshi MJ, Melby MJ, Kaback KR, et al.: Medication-related visits to the emergency department: a prospective study. Ann Pharmacother. 1999, 33:1252–1257.
Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279:1200–1205. This reference is important because it is one of the largest metaanalyses on the incidence of adverse drug reactions.
Bigby M: Rates of cutaneous reaction to drugs. Arch Dermatol 2001, 137:765–770.
Silbert IB, Epstein JW: The treatment of chorea with phenylethyl-hydantoin: a study of 28 cases. Arch Pediatr 1934, 51:373–382.
Brown TS, Appel JE, Kasteler JS, et al.: Hypersensitivity reaction in a child due to lamotrigine. Pediatr Dermatol 1999, 16:46–49.
Mylonakis E, Vittorio CC, Hollik DA, et al.: Lamotrigine overdose presenting as anticonvulsant hypersensitivity syndrome. Ann Pharmacother 1999, 33:557–559.
Schlienger RG, Knowles SR, Shear NH: Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998, 51:1172–1175.
Licata AL, Louis ED: Anticonvulsant hypersensitivity syndrome. Compr Ther 1996, 22:152–155.
Hebert AA, Ralston JP: Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 2001, 62(suppl 14):22–26. Excellent review article describing clinical spectrum of cutaneous reactions to antiepileptics with recommendations for treatment.
Knowles SR, Shapiro LE, Shear NH: Anticonvulsant hypersensitivity syndrome: incidence, prevention, management. Drug Safety 1999, 17:503–506.
Tennis P, Stern R: Risk of serious cutaneous disorders after initiation of the use of phenytoin, cabamazepine, or sodium valproate: a record linkage study. Neurology 1997, 49:542–546.
Disabilities among children aged < 17 years—United States, 1991–1992. MMWR Morb Mortal Wkly Rep 1995, 44:609-612.
Current trends in prevalence of self-reported epilepsy—United States, 1986–1990. MMWR Morb Mortal Wkly Rep 1994, 43:810–811, 817–818.
Gennis MA, Vemuri R, Burns EA, et al.: Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991, 91:631–634.
Aihara M, Sugita Y, Takahashi S, et al.: Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol 2001, 144:1231–1234.
Kennebeck GA: Anticonvulsant hypersensitivity syndrome. J Am Board Fam Pract 2000, 13:364–370.
Morkunas AR, Miller MB: Anticonvulsant hypersensitivity syndrome. Crit Care Clin 1997, 13:727–739.
Rzany B, Correia O, Kelly JP, et al.: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999, 353:2190–2194.
Bessmertny O, Hatton RC, Gonzalez-Peralta RP: Antiepileptic hypersensitivity syndrome in children. Ann Pharmacother 2001, 35:533–538. The only published case series describing clinical features, management, and outcomes of antiepileptic hypersensitivity syndrome in pediatric patients.
Prosser TR, Lander R: Phenytoin-induced hypersensitivity reactions. Clin Pharm 1987, 6:728–734.
Haruda F: Phenytoin hypersensitivity: 38 cases. Neurology 1979, 29:1480–1485.
Chinen J, Piecuch S: Anticonvulsant hypersensitivity syndrome vs Kawasaki disease: a challenging clinical diagnosis with therapeutic implications. Clin Pediatr 2000, 39:109–111.
Neuman MG, Malkiewicz IM, Shear NH: A novel lymphocyte toxicity assay to assess drug hypersensitivity syndrome. Clin Biochem 2000, 33:517–524. One of the few published reports with a detailed description of lymphocyte toxicity assay.
Guberman AH, Besag FMC, Brodie MJ, et al.: Lamotrigineassociated rash: risk/benefit considerations in adults and children. Epilepsia 1999, 40:985–991.
Vick NA: Suppression of carbamazepine-induced skin rash with prednisone. N Engl J Med 1983, 309:1193–1194.
Murphy JM, Mashman J, Miller JD, et al.: Suppression of carbamazepine-induced rash with prednisone. Neurology 1991, 41:144–145.
Straussberg R, Harel L, Ben-Amitai D, et al.: Carbamazepineinduced Stevens-Johnson syndrome treated with IV steroids and IVIG. Pediatr Neurol 2000, 22:231–233.
Scheuerman O, Nofech-Moses Y, Rachmel A, et al.: Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin. Pediatrics 2001, 107(1):E14.
Griebel ML: Acute management of hypersensivitivy reactions and seizures. Epilepsia 1998, 39(suppl 7):S17-S21.
Shear NH, Spielberg SP: Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988, 82:1826–1832.
DeToledo JC, Minagar A, Lowe MR, et al.: Skin eruption with gabapentin in a patient with repeated AED-induced Stevens-Johnson’s syndrome. Ther Drug Monit 1999, 21:137–138.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bessmertny, O., Pham, T. Antiepileptic hypersensitivity syndrome: Clinicians beware and be aware. Curr Allergy Asthma Rep 2, 34–39 (2002). https://doi.org/10.1007/s11882-002-0035-9
Issue Date:
DOI: https://doi.org/10.1007/s11882-002-0035-9